Pharma-Bio Serv, Inc. (PBSV) — SEC Filings
Pharma-Bio Serv, Inc. (PBSV) — 15 SEC filings. Latest: 10-Q (Sep 15, 2025). Includes 6 10-Q, 3 8-K, 2 DEF 14A.
View Pharma-Bio Serv, Inc. on SEC EDGAR
Overview
Pharma-Bio Serv, Inc. (PBSV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Sep 15, 2025: Pharma-Bio Serv, Inc. (PBSV) reported a net loss of $204,250 for the three months ended July 31, 2025, a 33.9% improvement from the $309,194 net loss in the same period last year. For the nine months ended July 31, 2025, the net loss significantly decreased to $100,361 from $793,730 in the prior yea
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 14 neutral, 1 mixed. The dominant filing sentiment for Pharma-Bio Serv, Inc. is neutral.
Filing Type Overview
Pharma-Bio Serv, Inc. (PBSV) has filed 6 10-Q, 3 8-K, 2 DEF 14A, 2 10-K/A, 2 10-K with the SEC between Jan 2024 to Sep 2025.
Filings by Year
Recent SEC Filings (15)
Risk Profile
Risk Assessment: Of PBSV's 14 recent filings, 0 were flagged as high-risk, 3 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $6,851,460 |
| Net Income | $(100,361) |
| EPS | $(0.004) |
| Debt-to-Equity | 0.13 |
| Cash Position | $3,957,752 |
| Operating Margin | -7.4% |
| Total Assets | $13,585,578 |
| Total Debt | $1,658,894 |
Key Executives
- Pedro J. Lasanta
Industry Context
Pharma-Bio Serv, Inc. operates in the technical compliance consulting services sector, serving the pharmaceutical and biotechnology industries. This sector is characterized by stringent regulatory requirements and a constant need for specialized expertise to navigate complex compliance landscapes. Key trends include the increasing complexity of global regulations, the growing demand for outsourced compliance services, and the need for companies to maintain high standards in drug development and manufacturing.
Top Tags
10-Q (4) · Pharma-Bio Serv (4) · Puerto Rico (3) · 8-K (2) · financials (2) · corporate-governance (2) · annual-report (2) · filing (2) · 10-K (2) · consulting (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenues (3 months ended July 31, 2025) | $1,963,083 | Decreased by 18.8% from $2,418,163 in the prior year period. |
| Revenues (9 months ended July 31, 2025) | $6,851,460 | Decreased by 4.5% from $7,175,967 in the prior year period. |
| Net Loss (3 months ended July 31, 2025) | $(204,250) | Improved by 33.9% from $(309,194) in the prior year period. |
| Net Loss (9 months ended July 31, 2025) | $(100,361) | Improved by 87.4% from $(793,730) in the prior year period. |
| Cash and Cash Equivalents (July 31, 2025) | $3,957,752 | Decreased by 41.5% from $6,767,356 at October 31, 2024. |
| Cash Dividends Paid (9 months ended July 31, 2025) | $1,719,918 | Significant cash outflow to shareholders. |
| Total Assets (July 31, 2025) | $13,585,578 | Decreased by 16.6% from $16,292,230 at October 31, 2024. |
| Gross Profit (9 months ended July 31, 2025) | $2,161,097 | Increased by 20.8% from $1,789,468 in the prior year period. |
| Allowance for Credit Losses (July 31, 2025) | $5.3 million | Related to an account being litigated since 2021. |
| Common Shares Outstanding (September 10, 2025) | 22,918,092 | Total shares outstanding as of a recent date. |
| Fiscal Year End | 1031 | Indicates the end of the company's financial reporting year. |
| Net Sales | $56.15M | Q1 2025 revenue |
| Total Assets | $235.20M | As of January 31, 2025 |
| Accounts Receivable | $22.96M | As of January 31, 2025 |
| SEC File Number | 000-50956 | Identifies the company's filings with the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Pharma-Bio Serv, Inc. (PBSV)?
Pharma-Bio Serv, Inc. has 15 recent SEC filings from Jan 2024 to Sep 2025, including 6 10-Q, 3 8-K, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PBSV filings?
Across 15 filings, the sentiment breakdown is: 14 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Pharma-Bio Serv, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Pharma-Bio Serv, Inc. (PBSV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Pharma-Bio Serv, Inc.?
Key financial highlights from Pharma-Bio Serv, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PBSV?
The investment thesis for PBSV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Pharma-Bio Serv, Inc.?
Key executives identified across Pharma-Bio Serv, Inc.'s filings include Pedro J. Lasanta.
What are the main risk factors for Pharma-Bio Serv, Inc. stock?
Of PBSV's 14 assessed filings, 0 were flagged high-risk, 3 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Pharma-Bio Serv, Inc.?
Forward guidance and predictions for Pharma-Bio Serv, Inc. are extracted from SEC filings as they are enriched.